King Minos II hall
King Minos III hall
Hands-on training
N.1Β. US-guided fistula needling
Quality & safety in Dialysis Units
N.2B. Quality of services and patient safety
1. Quality in practice - Diaverum paradigm
2. TBC
3. TBC
Nursing
N.3B. Renal nursing
1. TBC
2. Dry weight assessment
3. Intradialytic BP disorders: assesment & management
_edited_edited_edited.jpg){kind=small}
Hands-on training
N.3B. Course on BLS with the use of external defibrillator
Poster session
N.1A. e-Poster
Hypertension
N.3A. Hypertension
1. Management of hypertension in patients with CKD
2. Resistant hypertension
3. Use of diuretics in CKD: benefits and risks
4. Hypertension in dialysis
Breakthrough in Nephrology
N.2A. Changing the status quo in CKD
1. SGLT2 inhibitors: what's new?
2. The place of GLP-1 agonists in clinical practice
3. The place of MRAs in clinical practice
Cardiovascular morbidity
N.5A. Cardiovascular morbidity in CKD
1. Treatment on hyperlipidaemia: what's new?
2. Challenges in the management of heart failure in patients with CKD
3. Update in the management of hyperkalaemia
Clinical Nephrology
N.4A. IgA nephropathy
1. The role of B cells and BAFF/APRIL
2. New and emerging therapies in IgA nephropathy
3. How should I manage the patient with IgA nephropathy
General assembly
Hereditary nephropathies
N.6A. Polycystic kidney disease
1. Safety and effectiveness of Tolvaptan
2. New KDIGO Guidelines
3. Genetic tests: what should I know?
N.7A. Other hereditary nephropathies
1. Fabry Disease: what should I know?
2. Type-4 collagen gene mutation related nephropathies
3. Hereditary tubulointerstitial nephropathies
Haemodialysis
N.8A. Haemodialysis
1. Management of bone mineral disease: what is the target and how to achieve it
2. Uremic pruritus: systematic review, evaluation and management
3. HIF inhibitors: their place in clinical practice
Lunch
Close
Approved by:
Participants:
